Pharsight

1. Drug name - AFINITOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131	NOVARTIS	Cancer treatment	Nov, 2025 (3 years from now)
US8410131 (Pediatric)	NOVARTIS	Cancer treatment	May, 2026 (3 years from now)
US9006224	NOVARTIS	Neuroendocrine tumor treatment	Jul, 2028 (5 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
7.5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

2. Drug name - AMTURNIDE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295	NOVARTIS	Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic	May, 2023 (7 months from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE;EQ 5MG BASE;12.5MG	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 5MG BASE;12.5MG	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 5MG BASE;25MG	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 10MG BASE;12.5MG	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 10MG BASE;25MG	TABLET;ORAL	Discontinued

3. Drug name - ARCAPTA NEOHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721	NOVARTIS	Beta2-adrenoceptor agonists	Feb, 2025 (2 years from now)
CN1156451C	NOVARTIS	Adrenoreceptor Agonist	Jun, 2020 (2 years ago)
CN1353692A	NOVARTIS	Adrenoreceptor Agonist	Jun, 2020 (2 years ago)
IN222346B	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
IN200101673P4	NOVARTIS	Beta 2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP2332915A1	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP2332915B1	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP1183240A1	NOVARTIS	Beta2-Adrenoceptor Agonists	Nov, 2024 (2 years from now)
EP1183240B1	NOVARTIS	Beta2-Adrenoceptor Agonists	Nov, 2024 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730	NOVARTIS	Inhaler device	Oct, 2028 (6 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 75MCG BASE	POWDER;INHALATION	Discontinued

4. Drug name - CIPRODEX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650	NOVARTIS	Method of treating middle ear infections	Jun, 2025 (2 years from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS;OTIC

Strength	Dosage	Availability
0.3%;0.1%	SUSPENSION/DROPS;OTIC	Prescription

5. Drug name - EXFORGE HCT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475839	NOVARTIS	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	May, 2023 (7 months from now)
US8101599	NOVARTIS	Pharmaceutical composition containing anti-hypertensive agents	May, 2023 (7 months from now)
US8475839 (Pediatric)	NOVARTIS	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same	Nov, 2023 (1 year, 1 month from now)

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE;12.5MG;160MG	TABLET;ORAL	Prescription
EQ 5MG BASE;25MG;160MG	TABLET;ORAL	Prescription
EQ 10MG BASE;12.5MG;160MG	TABLET;ORAL	Prescription
EQ 10MG BASE;25MG;160MG	TABLET;ORAL	Prescription
EQ 10MG BASE;25MG;320MG	TABLET;ORAL	Prescription

6. Drug name - GILENYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283	NOVARTIS	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	Mar, 2026 (3 years from now)
US8324283 (Pediatric)	NOVARTIS	Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol	Sep, 2026 (3 years from now)
US9187405	NOVARTIS	S1P receptor modulators for treating relasping-remitting multiple sclerosis	Jun, 2027 (4 years from now)
US9187405 (Pediatric)	NOVARTIS	S1P receptor modulators for treating relasping-remitting multiple sclerosis	Dec, 2027 (5 years from now)
US10543179	NOVARTIS	Dosage regimen of an S1P receptor modulator	Dec, 2027 (5 years from now)
US9592208	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Mar, 2032 (9 years from now)
US9592208 (Pediatric)	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Sep, 2032 (9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

7. Drug name - HYCAMTIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645	NOVARTIS	Compound, corresponding compositions, preparation and/or treatment methods	Dec, 2024 (2 years from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 1MG BASE	CAPSULE;ORAL	Prescription

8. Drug name - ILEVRO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295	NOVARTIS	Ophthalmic compositions containing a synergistic combination of two polymers	Jun, 2024 (1 year, 8 months from now)
US9662398	NOVARTIS	Carboxylvinyl polymer-containing nanoparticle suspensions	Dec, 2030 (8 years from now)
US8921337	NOVARTIS	Carboxyvinyl polymer-containing nanoparticle suspensions	Mar, 2032 (9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.3%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

9. Drug name - IZBA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (6 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (6 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (7 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.003%	SOLUTION/DROPS;OPHTHALMIC	Discontinued

10. Drug name - KISQALI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Jun, 2028 (5 years from now)
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)
US9193732	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (9 years from now)
CN103201275A	NOVARTIS	Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof	Dec, 2015 (6 years ago)
CN103788100A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Jun, 2017 (5 years ago)
CN101594871A	NOVARTIS	Pyrrolopyrimidine Compounds And Use Thereof	May, 2027 (4 years from now)
CN101594871B	NOVARTIS	Pyrrolopyrimidine Compounds And Use Thereof	May, 2027 (4 years from now)
CN102186856B	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN102186856A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN105384741B	NOVARTIS	A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof	Nov, 2031 (9 years from now)
CN105384741A	NOVARTIS	Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof	Nov, 2031 (9 years from now)
IN283133B	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
IN200809406P1	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2029145B1	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2029145A2	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2331547A1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547B1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2638030A1	NOVARTIS	Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof	Nov, 2031 (9 years from now)
EP2638030B1	NOVARTIS	Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof	Nov, 2031 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (7 years from now)
US9868739	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (9 years from now)
US10799506	NOVARTIS	Ribociclib tablet	Apr, 2036 (13 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

11. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Jun, 2028 (5 years from now)
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)
US9193732	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (9 years from now)
CN103201275A	NOVARTIS	Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof	Dec, 2015 (6 years ago)
CN103788100A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Jun, 2017 (5 years ago)
CN101594871A	NOVARTIS	Pyrrolopyrimidine Compounds And Use Thereof	May, 2027 (4 years from now)
CN101594871B	NOVARTIS	Pyrrolopyrimidine Compounds And Use Thereof	May, 2027 (4 years from now)
CN102186856B	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN102186856A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN105384741B	NOVARTIS	A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof	Nov, 2031 (9 years from now)
CN105384741A	NOVARTIS	Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof	Nov, 2031 (9 years from now)
IN283133B	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
IN200809406P1	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2029145B1	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2029145A2	NOVARTIS	Pyrrolopyrimidine Compounds And Their Uses	May, 2027 (4 years from now)
EP2331547A1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547B1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2638030A1	NOVARTIS	Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof	Nov, 2031 (9 years from now)
EP2638030B1	NOVARTIS	Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof	Nov, 2031 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (7 years from now)
US9868739	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (9 years from now)
US10799506	NOVARTIS	Ribociclib tablet	Apr, 2036 (13 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;EQ 200MG BASE	TABLET;ORAL	Prescription

12. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213	NOVARTIS	Compositions and methods for inhibiting expression of a target gene	Mar, 2022 (6 months ago)
US8546143	NOVARTIS	Compositions and methods for inhibiting expression of a target gene	Apr, 2022 (5 months ago)
US8232383	NOVARTIS	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)	Feb, 2023 (4 months from now)
US11078485	NOVARTIS	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Nov, 2023 (1 year, 29 days from now)
US9708610	NOVARTIS	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (1 year, 2 months from now)
US10669544	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US10273477	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US9708615	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US8809292	NOVARTIS	Compositions and methods for inhibiting expression of the PCSK9 gene	May, 2027 (4 years from now)
US10131907	NOVARTIS	Glycoconjugates of RNA interference agents	Aug, 2028 (5 years from now)
US8828956	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (6 years from now)
US10806791	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (6 years from now)
US9370582	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (6 years from now)
US8106022	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (7 years from now)
US10125369	NOVARTIS	PCSK9 iRNA compositions and methods of use thereof	Aug, 2034 (11 years from now)
CN1312856A	NOVARTIS	Enzymatic Nucleic Acid Treatment Of Diseases Or Conditions Associated With Hepatitis C Virus Infection	Nov, 2004 (17 years ago)
CN1630724A	NOVARTIS	Method For Inhibiting Expression Of Target Gene	Jan, 2007 (15 years ago)
CN1608131A	NOVARTIS	Medicine For Treating Pancreatic Cancer	Jan, 2009 (13 years ago)
CN1608133A	NOVARTIS	Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers	Sep, 2009 (13 years ago)
CN1604783A	NOVARTIS	The Medicine For Treating Fibrosis Disease By Rna Interference	Dec, 2009 (12 years ago)
CN1650010A	NOVARTIS	Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease	Jan, 2010 (12 years ago)
CN101605892A	NOVARTIS	Rna Interference Mediated Inhibition Of Hepatitis C Virus	Aug, 2012 (10 years ago)
CN102124107A	NOVARTIS	Rna Interference Mediated Inhibition Of Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Gene Expression Using Short Interfering Nucleic Acid (Sina)	May, 2013 (9 years ago)
CN101426912A	NOVARTIS	Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference	Jun, 2013 (9 years ago)
CN102006890A	NOVARTIS	Targeting Lipid	Oct, 2015 (6 years ago)
CN101484588B	NOVARTIS	Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene	May, 2019 (3 years ago)
CN101484588A	NOVARTIS	Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene	May, 2019 (3 years ago)
CN1835897A	NOVARTIS	Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank	Aug, 2024 (1 year, 10 months from now)
CN1835897B	NOVARTIS	Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank	Aug, 2024 (1 year, 10 months from now)
CN104854242A	NOVARTIS	Pcsk9 Irna Composition And Using Method Thereof	Dec, 2033 (11 years from now)
CN104854242B	NOVARTIS	Pcsk9 Irna Composition And Using Method Thereof	Dec, 2033 (11 years from now)
IN200300537P3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN213846B	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN200300572P3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
IN203882B	NOVARTIS	Method For Inhibiting The Expression Of A Targe Gene	Jan, 2022 (8 months ago)
IN200806166P4	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
IN269138B	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
IN368763B	NOVARTIS	Pcsk9 Irna Compositions And Methods Of Use Thereof	Dec, 2033 (11 years from now)
IN201503007P4	NOVARTIS	Pcsk9 Irna Compositions And Methods Of Use Thereof	Dec, 2033 (11 years from now)
EP748382B1	NOVARTIS	Non-Nucleotide Containing Enzymatic Nucleic Acid	Aug, 2014 (8 years ago)
EP748382A1	NOVARTIS	Non-Nucleotide Containing Enzymatic Nucleic Acid	Aug, 2014 (8 years ago)
EP725788B1	NOVARTIS	2'-Amido And 2'-Peptido Modified Oligonucleotides	Oct, 2014 (7 years ago)
EP725788A1	NOVARTIS	2'-Amido And 2'-Peptido Modified Oligonucleotides	Oct, 2014 (7 years ago)
EP728205B1	NOVARTIS	Reagent For Treatment Of Arthritic Conditions	Nov, 2014 (7 years ago)
EP728205A1	NOVARTIS	Reagent For Treatment Of Arthritic Conditions	Nov, 2014 (7 years ago)
EP1408111A3	NOVARTIS	Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor	Oct, 2016 (5 years ago)
EP1408111B1	NOVARTIS	Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor	Oct, 2016 (5 years ago)
EP1408111A2	NOVARTIS	Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor	Oct, 2016 (5 years ago)
EP928290B9	NOVARTIS	Oligoribonucleotides And Ribonucleases For Cleaving Rna	Jun, 2017 (5 years ago)
EP928290A4	NOVARTIS	Oligoribonucleotides And Ribonucleases For Cleaving Rna	Jun, 2017 (5 years ago)
EP928290A1	NOVARTIS	Oligoribonucleotides And Ribonucleases For Cleaving Rna	Jun, 2017 (5 years ago)
EP928290B1	NOVARTIS	Oligoribonucleotides And Ribonucleases For Cleaving Rna	Jun, 2017 (5 years ago)
EP1214945A2	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1214945A3	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP2363479B1	NOVARTIS	Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene	Jan, 2020 (2 years ago)
EP1214945B2	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1550719B1	NOVARTIS	Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1214945B1	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1550719A1	NOVARTIS	Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP2363479A1	NOVARTIS	Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene	Jan, 2020 (2 years ago)
EP1144623A1	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1144623B9	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1144623B1	NOVARTIS	Method And Medicament For Inhibiting The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1798285B1	NOVARTIS	Methods And Medicament For Inhibition The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1798285A1	NOVARTIS	Methods And Medicament For Inhibition The Expression Of A Defined Gene	Jan, 2020 (2 years ago)
EP1349927B1	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease	May, 2021 (1 year, 4 months ago)
EP1349927A2	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease	May, 2021 (1 year, 4 months ago)
EP1352061A2	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B9	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP1352061B1	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene	Jan, 2022 (8 months ago)
EP2213736B1	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736A3	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2213736A2	NOVARTIS	Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness	Jan, 2022 (8 months ago)
EP2415486B1	NOVARTIS	Conjugates And Compositions For Cellular Delivery	May, 2022 (4 months ago)
EP2415486A2	NOVARTIS	Conjugates And Compositions For Cellular Delivery	May, 2022 (4 months ago)
EP2415486A3	NOVARTIS	Conjugates And Compositions For Cellular Delivery	May, 2022 (4 months ago)
EP1423404A2	NOVARTIS	Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423404A4	NOVARTIS	Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423404B1	NOVARTIS	Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2278004A1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2287305A1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1458741B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid	Feb, 2023 (4 months from now)
EP2902406A1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1572128B1	NOVARTIS	Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1458741A2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid	Feb, 2023 (4 months from now)
EP2287305B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2287306B2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1572128A4	NOVARTIS	Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2287305B2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2287306A1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1572128A2	NOVARTIS	Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423406A4	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2902406B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1458741A4	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid	Feb, 2023 (4 months from now)
EP3354656A1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423406A2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423406B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1430157A4	NOVARTIS	Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1430157B1	NOVARTIS	Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP3354656B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1423406B2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1430157A2	NOVARTIS	Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2287306B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP2278004B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)	Feb, 2023 (4 months from now)
EP1562971A2	NOVARTIS	Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1560840A4	NOVARTIS	Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1562971B1	NOVARTIS	Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP2957568B1	NOVARTIS	Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1560840B1	NOVARTIS	Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1562971A4	NOVARTIS	Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1560840A2	NOVARTIS	Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP2957568A1	NOVARTIS	Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation	Nov, 2023 (1 year, 29 days from now)
EP1605978A2	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978A4	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407B1	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978B1	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A3	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A2	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1615611A2	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611A4	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611B1	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1620544A4	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544A2	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544B1	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1622572A2	NOVARTIS	Conjugates And Compositions For Cellular Delivery	Apr, 2024 (1 year, 6 months from now)
EP1622572B1	NOVARTIS	Conjugates And Compositions For Cellular Delivery	Apr, 2024 (1 year, 6 months from now)
EP1622572A4	NOVARTIS	Conjugates And Compositions For Cellular Delivery	Apr, 2024 (1 year, 6 months from now)
EP1627061B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)	May, 2024 (1 year, 7 months from now)
EP1627061A2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)	May, 2024 (1 year, 7 months from now)
EP1765074A4	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 7 months from now)
EP1765074A2	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 7 months from now)
EP1765074B1	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 7 months from now)
EP1667944B1	NOVARTIS	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1667944A1	NOVARTIS	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1664299A1	NOVARTIS	Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)	Sep, 2024 (1 year, 11 months from now)
EP1664299B1	NOVARTIS	Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)	Sep, 2024 (1 year, 11 months from now)
EP1677822B1	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822A2	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822A4	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1713915A2	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)	Feb, 2025 (2 years from now)
EP1713915B1	NOVARTIS	Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)	Feb, 2025 (2 years from now)
EP1799270B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes	Sep, 2025 (2 years from now)
EP1799270A2	NOVARTIS	Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes	Sep, 2025 (2 years from now)
EP1799270A4	NOVARTIS	Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes	Sep, 2025 (2 years from now)
EP1931781B1	NOVARTIS	Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference	Aug, 2026 (3 years from now)
EP1931781A2	NOVARTIS	Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference	Aug, 2026 (3 years from now)
EP2584047B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3249052B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584048A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2835429B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3578656A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2835429A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2194128B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3578656B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2194128A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584048B1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2584047A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP3249052A1	NOVARTIS	Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene	May, 2027 (4 years from now)
EP2231195B1	NOVARTIS	Targeting Lipids	Dec, 2028 (6 years from now)
EP2231194A2	NOVARTIS	Folate-Irna Conjugates	Dec, 2028 (6 years from now)
EP2231194B1	NOVARTIS	Folate-Irna Conjugates	Dec, 2028 (6 years from now)
EP3156077A1	NOVARTIS	Targeting Lipids	Dec, 2028 (6 years from now)
EP3156077B1	NOVARTIS	Targeting Lipids	Dec, 2028 (6 years from now)
EP2231195A2	NOVARTIS	Targeting Lipids	Dec, 2028 (6 years from now)
EP2929031B9	NOVARTIS	Pcsk9 Irna Compositions And Methods Of Use Thereof	Dec, 2033 (11 years from now)
EP2929031A1	NOVARTIS	Pcsk9 Irna Compositions And Methods Of Use Thereof	Dec, 2033 (11 years from now)
EP2929031B1	NOVARTIS	Pcsk9 Irna Compositions And Methods Of Use Thereof	Dec, 2033 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825	NOVARTIS	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Nov, 2023 (1 year, 29 days from now)
US8222222	NOVARTIS	Compositions and methods for inhibiting expression of the PCSK9 gene	Dec, 2027 (5 years from now)
US10851377	NOVARTIS	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder	Aug, 2036 (13 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

13. Drug name - MAYZENT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519	NOVARTIS	Immunosuppresant compounds and compositions	May, 2024 (1 year, 7 months from now)
CN102174042B	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN102174042A	NOVARTIS	Immunosuppressant Compound And Composition	Jul, 2015 (7 years ago)
CN1791592A	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1787817A	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1791592B	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1787817B	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1816544B	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1816544A	NOVARTIS	Immunosuppressant Compounds And Compositions	Jul, 2015 (7 years ago)
CN1791395A	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
CN1791395B	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
IN234287B	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
IN200503060P4	NOVARTIS	Immunosuppresant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP2514743A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336A2	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP2514743B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551A2	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441	NOVARTIS	Dosage regimen of an S1P receptor agonist	Nov, 2030 (8 years from now)

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 2MG BASE	TABLET;ORAL	Prescription

14. Drug name - MEKINIST

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423	NOVARTIS	Pyrimidine compound and medical use thereof	May, 2027 (4 years from now)
US8703781	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Oct, 2030 (8 years from now)
CN101912400A	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
CN101006086A	NOVARTIS	5-Amido-2, 4, 7-Trioxy-3, 4, 7, 8-Tetrahydropyranyl Ether-2H-Naphthyridine [2,3-D] Pyrimidine Derivatives And Correlative Compound Used For Curing Cancer	Jun, 2025 (2 years from now)
CN101912400B	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
CN101006086B	NOVARTIS	For The 5 - -2, 4, 7 - -3, 4, 7, 8-Tetrahydro - -2H - Pyrido [2, 3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
CN102655753A	NOVARTIS	Combination	Oct, 2030 (8 years from now)
CN102655753B	NOVARTIS	Combined Medicine	Oct, 2030 (8 years from now)
IN200700102P4	NOVARTIS	Pyrimidine Compound And Medical Use Thereof	Jun, 2025 (2 years from now)
IN237689B	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyridio[2,3-D]Pyrimidine Derivatives And A Pharmaceutical Composition Comprising The Same	Jun, 2025 (2 years from now)
EP2298768B9	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
EP2298768B1	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
EP2298768A1	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
EP1761528A1	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
EP1761528B1	NOVARTIS	5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer	Jun, 2025 (2 years from now)
EP2488033A1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
EP2488033B1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
EP2488033A4	NOVARTIS	Combination	Oct, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443	NOVARTIS	Pyrimidine compound and medical use thereof	Jun, 2025 (2 years from now)
US8952018	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Oct, 2030 (8 years from now)
US8580304	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9399021	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9271941	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9155706	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US10869869	NOVARTIS	Method of adjuvant cancer treatment	Aug, 2033 (10 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

15. Drug name - MOXEZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311	NOVARTIS	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (6 years from now)
US9114168	NOVARTIS	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.5% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

16. Drug name - NEVANAC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324281	NOVARTIS	Topical nepafenac formulations	Dec, 2025 (3 years from now)
US8071648	NOVARTIS	Topical nepafenac formulations	Dec, 2025 (3 years from now)
US7834059	NOVARTIS	Topical nepafenac formulations	Jan, 2027 (4 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: Method of treating ocular inflammation

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.1%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

17. Drug name - PATANASE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977376	NOVARTIS	Olopatadine formulations for topical nasal administration	Feb, 2023 (3 months from now)
US8399508 (Pediatric)	NOVARTIS	Olopatadine formulations for topical nasal administration	Mar, 2023 (5 months from now)
US7977376 (Pediatric)	NOVARTIS	Olopatadine formulations for topical nasal administration	Aug, 2023 (9 months from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.665MG/SPRAY	SPRAY, METERED;NASAL	Prescription

18. Drug name - PIQRAY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2029 (6 years from now)
US8227462	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2030 (7 years from now)
CN102149711B	NOVARTIS	Organic Compounds	Sep, 2029 (6 years from now)
CN102149711A	NOVARTIS	Organic Compounds	Sep, 2029 (6 years from now)
IN307469B	NOVARTIS	The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)	Sep, 2029 (6 years from now)
EP2331537A1	NOVARTIS	1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases	Sep, 2029 (6 years from now)
EP2331537B1	NOVARTIS	1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases	Sep, 2029 (6 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

19. Drug name - PROMACTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870	NOVARTIS	Thrombopoietin mimetics	Nov, 2022 (a month from now)
US7547719	NOVARTIS	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	Jul, 2025 (2 years from now)
CN101343250A	NOVARTIS	Thrombopoietin Mimics	May, 2020 (2 years ago)
CN101343251B	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN101343250B	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN101343251A	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN100423721C	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
CN1444477A	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
CN100542530C	NOVARTIS	3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine)	May, 2023 (7 months from now)
CN1652842A	NOVARTIS	3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine)	May, 2023 (7 months from now)
IN200201666P3	NOVARTIS	A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production	May, 2021 (1 year, 4 months ago)
IN213176B	NOVARTIS	A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production	May, 2021 (1 year, 4 months ago)
IN200403400P1	NOVARTIS	3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
IN233161B	NOVARTIS	3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1889838B1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1889838A1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981A1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981B1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981B8	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1534390B1	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1534390A2	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1534390A4	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1294378A2	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
EP1294378B1	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
EP1294378A4	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870 (Pediatric)	NOVARTIS	Thrombopoietin mimetics	May, 2023 (7 months from now)
US7795293	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	May, 2023 (7 months from now)
US7795293 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Nov, 2023 (1 year, 1 month from now)
US7547719 (Pediatric)	NOVARTIS	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	Jan, 2026 (3 years from now)
US8828430	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8071129	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8062665	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8052994	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8052993	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Aug, 2027 (4 years from now)
US8062665 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Feb, 2028 (5 years from now)
US8071129 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Feb, 2028 (5 years from now)
US8828430 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Feb, 2028 (5 years from now)
US8052993 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Feb, 2028 (5 years from now)
US8052994 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Feb, 2028 (5 years from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG ACID	TABLET;ORAL	Prescription
EQ 25MG ACID	TABLET;ORAL	Prescription
EQ 50MG ACID	TABLET;ORAL	Prescription
EQ 75MG ACID	TABLET;ORAL	Prescription
EQ 100MG ACID	TABLET;ORAL	Discontinued

20. Drug name - PROMACTA KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870	NOVARTIS	Thrombopoietin mimetics	Nov, 2022 (a month from now)
US7547719	NOVARTIS	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	Jul, 2025 (2 years from now)
CN101343250A	NOVARTIS	Thrombopoietin Mimics	May, 2020 (2 years ago)
CN101343251B	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN101343250B	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN101343251A	NOVARTIS	Thrombopoietin Mimetics	May, 2020 (2 years ago)
CN100423721C	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
CN1444477A	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
CN100542530C	NOVARTIS	3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine)	May, 2023 (7 months from now)
CN1652842A	NOVARTIS	3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine)	May, 2023 (7 months from now)
IN200201666P3	NOVARTIS	A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production	May, 2021 (1 year, 4 months ago)
IN213176B	NOVARTIS	A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production	May, 2021 (1 year, 4 months ago)
IN200403400P1	NOVARTIS	3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
IN233161B	NOVARTIS	3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1889838B1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1889838A1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981A1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981B1	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1864981B8	NOVARTIS	Thrombopoietin Mimetics	May, 2021 (1 year, 4 months ago)
EP1534390B1	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1534390A2	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1534390A4	NOVARTIS	3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)	May, 2023 (7 months from now)
EP1294378A2	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
EP1294378B1	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
EP1294378A4	NOVARTIS	Thrombopoietin Mimetics	Mar, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870 (Pediatric)	NOVARTIS	Thrombopoietin mimetics	May, 2023 (7 months from now)
US7795293	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	May, 2023 (7 months from now)
US7795293 (Pediatric)	NOVARTIS	3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)	Nov, 2023 (1 year, 1 month from now)
US7547719 (Pediatric)	NOVARTIS	3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)	Jan, 2026 (3 years from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
EQ 12.5MG ACID/PACKET	FOR SUSPENSION;ORAL	Prescription
EQ 25MG ACID/PACKET	FOR SUSPENSION;ORAL	Prescription

21. Drug name - RECLAST

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987	NOVARTIS	Method of administering bisphosphonates	Oct, 2023 (1 year, 21 days from now)
US7932241	NOVARTIS	Pharmaceutical products comprising bisphosphonates	Feb, 2028 (5 years from now)
US7932241 (Pediatric)	NOVARTIS	Pharmaceutical products comprising bisphosphonates	Aug, 2028 (5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
EQ 5MG BASE/100ML	INJECTABLE;INTRAVENOUS	Prescription

22. Drug name - RYDAPT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244	NOVARTIS	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	Oct, 2022 (23 days from now)
US7973031	NOVARTIS	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	Oct, 2024 (2 years from now)
US8575146	NOVARTIS	Pharmaceutical uses of staurosporine derivatives	Dec, 2030 (8 years from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription

23. Drug name - SCEMBLIX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195	NOVARTIS	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1	May, 2033 (10 years from now)
CN104302638B	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302638A	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302634A	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302634B	NOVARTIS	For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives	May, 2033 (10 years from now)
EP2861579B9	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861576B1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861579A1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861579B1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861576A1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

24. Drug name - SEEBRI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730	NOVARTIS	Inhaler device	Oct, 2028 (6 years from now)
US8182838	NOVARTIS	Dry powder composition comprising co-jet milled particles for pulmonary inhalation	Oct, 2028 (6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
15.6MCG/INH	POWDER;INHALATION	Discontinued

25. Drug name - TAFINLAR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415345	NOVARTIS	Benzene sulfonamide thiazole and oxazole compounds	Jan, 2030 (7 years from now)
US7994185	NOVARTIS	Benzene sulfonamide thiazole and oxazole compounds	Jan, 2030 (7 years from now)
US8703781	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Oct, 2030 (8 years from now)
CN102083312A	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
CN102083312B	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
CN102655753A	NOVARTIS	Combination	Oct, 2030 (8 years from now)
CN102655753B	NOVARTIS	Combined Medicine	Oct, 2030 (8 years from now)
IN275655B	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
IN201004199P2	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
EP2282636A4	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
EP2282636B1	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
EP2282636A2	NOVARTIS	Benzene Sulfonamide Thiazole And Oxazole Compounds	May, 2029 (6 years from now)
EP2488033A1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
EP2488033B1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
EP2488033A4	NOVARTIS	Combination	Oct, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443	NOVARTIS	Pyrimidine compound and medical use thereof	Jun, 2025 (2 years from now)
US9233956	NOVARTIS	Benzene sulfonamide thiazole and oxazole compounds	May, 2029 (6 years from now)
US8952018	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Oct, 2030 (8 years from now)
US10869869	NOVARTIS	Method of adjuvant cancer treatment	Aug, 2033 (10 years from now)

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test; Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	CAPSULE;ORAL	Prescription
EQ 75MG BASE	CAPSULE;ORAL	Prescription

26. Drug name - TASIGNA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169791	NOVARTIS	Inhibitors of tyrosine kinases	Jul, 2023 (8 months from now)
US8415363	NOVARTIS	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jul, 2026 (3 years from now)
US8163904	NOVARTIS	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	Aug, 2028 (5 years from now)
US9061029	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Apr, 2032 (9 years from now)
CN102358736A	NOVARTIS	4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide	Mar, 2015 (7 years ago)
CN102267981A	NOVARTIS	Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide	Jun, 2015 (7 years ago)
CN103804356A	NOVARTIS	4-Methyl-N-[3-(4-Methyl-Imidazol--1-Base)--5-Trifluoromethyl-Phenyl]--3-(4-Pyridin--3-Base-Pyrimidin--2-Ylamino)-Benzamide Of Crystalline Form	Mar, 2016 (6 years ago)
CN1675195A	NOVARTIS	Tyrosine Kinase Inhibitors	Jul, 2023 (8 months from now)
CN1324022C	NOVARTIS	Tyrosine Kinase Inhibitors	Jul, 2023 (8 months from now)
CN101228151B	NOVARTIS	Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
CN101228150B	NOVARTIS	4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide	Jul, 2026 (3 years from now)
CN101228150A	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
CN101228151A	NOVARTIS	Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Base-Pyrimidin-2-Yl-Amino)-Benzamide	Jul, 2026 (3 years from now)
CN102612368A	NOVARTIS	Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity	Nov, 2030 (8 years from now)
CN102612368B	NOVARTIS	Method Of Treating Proliferation Disorders And Other Pathological Conditions Mediated By Bar-Abl, C-Kit, Ddr1 Or Pdgf-R Kinase Activity	Nov, 2030 (8 years from now)
IN237430B	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
IN200403003P4	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
EP1532138B1	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
EP2357182A1	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
EP2357182B1	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
EP1532138A1	NOVARTIS	Inhibitors Of Tyrosine Kinases	Jul, 2023 (8 months from now)
EP2535337B1	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form	Jul, 2026 (3 years from now)
EP2535337A1	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form	Jul, 2026 (3 years from now)
EP1912973B1	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2284167A2	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2186808A1	NOVARTIS	Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP1910336B1	NOVARTIS	Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2284167B2	NOVARTIS	Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2284167B1	NOVARTIS	Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP1910336A1	NOVARTIS	Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2186808B1	NOVARTIS	Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP1912973A2	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2284167A3	NOVARTIS	Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide	Jul, 2026 (3 years from now)
EP2501384B1	NOVARTIS	Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity	Nov, 2030 (8 years from now)
EP2501384A1	NOVARTIS	Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity	Nov, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791 (Pediatric)	NOVARTIS	Inhibitors of tyrosine kinases	Jan, 2024 (1 year, 2 months from now)
US8501760	NOVARTIS	Pharmaceutical compositions comprising nilotinib or its salt	Jul, 2026 (3 years from now)
US8389537	NOVARTIS	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jul, 2026 (3 years from now)
US8415363 (Pediatric)	NOVARTIS	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jan, 2027 (4 years from now)
US8389537 (Pediatric)	NOVARTIS	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jan, 2027 (4 years from now)
US8501760 (Pediatric)	NOVARTIS	Pharmaceutical compositions comprising nilotinib or its salt	Jan, 2027 (4 years from now)
US8293756	NOVARTIS	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	Sep, 2027 (4 years from now)
US8293756 (Pediatric)	NOVARTIS	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	Mar, 2028 (5 years from now)
US8163904 (Pediatric)	NOVARTIS	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	Feb, 2029 (6 years from now)
US9061029 (Pediatric)	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Oct, 2032 (10 years from now)

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription
EQ 200MG BASE	CAPSULE;ORAL	Prescription

27. Drug name - TEKAMLO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949	NOVARTIS	Galenical formulations of organic compounds	Dec, 2029 (7 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE;EQ 5MG BASE	TABLET;ORAL	Discontinued
EQ 150MG BASE;EQ 10MG BASE	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 5MG BASE	TABLET;ORAL	Discontinued
EQ 300MG BASE;EQ 10MG BASE	TABLET;ORAL	Discontinued

28. Drug name - TRAVATAN Z

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8388941	NOVARTIS	Self preserved aqueous pharmaceutical compositions	Sep, 2027 (4 years from now)
US8323630	NOVARTIS	Self-preserved aqueous pharmaceutical compositions	Sep, 2027 (4 years from now)
US8268299	NOVARTIS	Self preserved aqueous pharmaceutical compositions	Oct, 2029 (7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.004%	SOLUTION/DROPS;OPHTHALMIC	Prescription

29. Drug name - TRIESENCE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880	NOVARTIS	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	Mar, 2029 (6 years from now)
US8128960	NOVARTIS	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	Dec, 2029 (7 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: Visualization during vitrectomy procedures; treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

Strength	Dosage	Availability
40MG/ML (40MG/ML)	INJECTABLE;INTRAVITREAL	Prescription

30. Drug name - TYKERB

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8821927	NOVARTIS	Pharmaceutical composition	Sep, 2029 (6 years from now)
CN101203211A	NOVARTIS	Medicine Composition	Apr, 2026 (3 years from now)
CN101203211B	NOVARTIS	Drug Composition	Apr, 2026 (3 years from now)
EP1871347A1	NOVARTIS	Pharmaceutical Composition	Apr, 2026 (3 years from now)
EP1871347A4	NOVARTIS	Pharmaceutical Composition	Apr, 2026 (3 years from now)
EP1871347B1	NOVARTIS	Pharmaceutical Composition	Apr, 2026 (3 years from now)

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 250MG BASE	TABLET;ORAL	Prescription

31. Drug name - TYZEKA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7858594	NOVARTIS	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	Sep, 2023 (11 months from now)
US7589079	NOVARTIS	Crystalline and amorphous forms of beta-L-2′-deoxythymidine	Sep, 2023 (11 months from now)
CN100376593C	NOVARTIS	L-2 ' - Deoxythymidine Of Crystallized And Amorphous	Aug, 2023 (9 months from now)
CN1714098A	NOVARTIS	L-2 ' - Deoxythymidine Of Crystallized And Amorphous	Aug, 2023 (9 months from now)
EP1534727B1	NOVARTIS	Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine	Aug, 2023 (9 months from now)
EP1534727A4	NOVARTIS	Crystalline And Amorphous Forms Of Beta-L-2 -Deoxythymidine	Aug, 2023 (9 months from now)
EP1534727A2	NOVARTIS	Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine	Aug, 2023 (9 months from now)

Drugs and Companies using TELBIVUDINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
600MG	TABLET;ORAL	Discontinued

32. Drug name - UTIBRON

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721	NOVARTIS	Beta2-adrenoceptor agonists	Feb, 2025 (2 years from now)
CN1156451C	NOVARTIS	Adrenoreceptor Agonist	Jun, 2020 (2 years ago)
CN1353692A	NOVARTIS	Adrenoreceptor Agonist	Jun, 2020 (2 years ago)
IN222346B	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
IN200101673P4	NOVARTIS	Beta 2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP2332915A1	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP2332915B1	NOVARTIS	Beta2-Adrenoceptor Agonists	Jun, 2020 (2 years ago)
EP1183240A1	NOVARTIS	Beta2-Adrenoceptor Agonists	Nov, 2024 (2 years from now)
EP1183240B1	NOVARTIS	Beta2-Adrenoceptor Agonists	Nov, 2024 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730	NOVARTIS	Inhaler device	Oct, 2028 (6 years from now)
US8182838	NOVARTIS	Dry powder composition comprising co-jet milled particles for pulmonary inhalation	Oct, 2028 (6 years from now)

Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
15.6MCG/INH;27.5MCG/INH	POWDER;INHALATION	Discontinued

33. Drug name - VALTURNA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168616	NOVARTIS	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension	Jul, 2026 (3 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE;160MG	TABLET;ORAL	Discontinued
EQ 300MG BASE;320MG	TABLET;ORAL	Discontinued

34. Drug name - VOTRIENT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7105530	NOVARTIS	Pyrimidineamines as angiogenesis modulators	Oct, 2023 (1 year, 13 days from now)
CN1549813A	NOVARTIS	As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis	Dec, 2021 (9 months ago)
CN1307173C	NOVARTIS	As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis	Dec, 2021 (9 months ago)
IN200300818P2	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Dec, 2021 (9 months ago)
IN210284B	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Dec, 2021 (9 months ago)
EP2311825A1	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Dec, 2021 (9 months ago)
EP2311825B1	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Dec, 2021 (9 months ago)
EP1343782B1	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Jun, 2025 (2 years from now)
EP1343782A1	NOVARTIS	Pyrimidineamines As Angiogenesis Modulators	Jun, 2025 (2 years from now)

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription
EQ 400MG BASE	TABLET;ORAL	Discontinued

35. Drug name - XIIDRA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7928122	NOVARTIS	Modulators of cellular adhesion	Nov, 2024 (2 years from now)
US7745460	NOVARTIS	Modulators of cellular adhesion	Nov, 2024 (2 years from now)
US7314938	NOVARTIS	Modulators of cellular adhesion	Mar, 2025 (2 years from now)
US8084047	NOVARTIS	Compositions and methods for treatment of eye disorders	May, 2026 (3 years from now)
US9890141	NOVARTIS	Crystalline pharmaceutical and methods of preparation and use thereof	Oct, 2030 (8 years from now)
CN105820160A	NOVARTIS	Cell Adhesion Regulator	Nov, 2024 (2 years from now)
CN1902195B	NOVARTIS	Cell Adhesion Regulator	Nov, 2024 (2 years from now)
CN105820160B	NOVARTIS	Cell Adhesion Regulator	Nov, 2024 (2 years from now)
CN1902195A	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
CN101175488B	NOVARTIS	Compositions And Methods For Treating Eye Disease	May, 2026 (3 years from now)
CN101175488A	NOVARTIS	Composition And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
IN279168B	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN200601233P2	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN201003759P2	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN250181B	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN201100459P2	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN348854B	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
IN284595B	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
IN200708114P1	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
EP1682537B1	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
EP1682537A1	NOVARTIS	Modulators Of Cellular Adhesion	Nov, 2024 (2 years from now)
EP1881823A4	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
EP1881823A1	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
EP2444079B1	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
EP1881823B1	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
EP2444079A1	NOVARTIS	Compositions And Methods For Treatment Of Eye Disorders	May, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216174	NOVARTIS	Modulators of cellular adhesion	Nov, 2024 (2 years from now)
US7790743	NOVARTIS	Modulators of cellular adhesion	Nov, 2024 (2 years from now)
US10124000	NOVARTIS	Modulators of cellular adhesion	Nov, 2024 (2 years from now)
US8592450	NOVARTIS	Compositions and methods for treatment of eye disorders	May, 2026 (3 years from now)
US8367701	NOVARTIS	Crystalline pharmaceutical and methods of preparation and use thereof	Apr, 2029 (6 years from now)
US9447077	NOVARTIS	Crystalline pharmaceutical and methods of preparation and use thereof	Apr, 2029 (6 years from now)
US8168655	NOVARTIS	Compositions and methods for treatment of eye disorders	May, 2029 (6 years from now)
US9353088	NOVARTIS	Crystalline pharmaceutical and methods of preparation and use thereof	Oct, 2030 (8 years from now)
US8927574	NOVARTIS	Crystalline pharmaceutical and methods of preparation and use thereof	Nov, 2030 (8 years from now)
US9085553	NOVARTIS	LFA-1 inhibitor and methods of preparation and polymorph thereof	Jul, 2033 (10 years from now)
US11058677	NOVARTIS	LFA-1 inhibitor formulations	Dec, 2033 (11 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
5%	SOLUTION/DROPS;OPHTHALMIC	Prescription

36. Drug name - ZOMETA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189	NOVARTIS	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	May, 2025 (2 years from now)
US8324189 (Pediatric)	NOVARTIS	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases	Nov, 2025 (3 years from now)
US7932241	NOVARTIS	Pharmaceutical products comprising bisphosphonates	Feb, 2028 (5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Multiple myeloma; bone metastases; hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
EQ 4MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INTRAVENOUS	Discontinued
EQ 4MG BASE/5ML	INJECTABLE;INTRAVENOUS	Prescription
EQ 4MG BASE/100ML	INJECTABLE;INTRAVENOUS	Prescription

37. Drug name - ZYKADIA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835430	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (3 months from now)
US9018204	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (3 months from now)
US8188276	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (3 months from now)
US9416112	NOVARTIS	2,4-pyrimidinediamine compounds and their uses	Jan, 2023 (3 months from now)
US7893074	NOVARTIS	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	Apr, 2026 (3 years from now)
US8399450	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Nov, 2027 (5 years from now)
US7964592	NOVARTIS	2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders	Apr, 2028 (5 years from now)
US8039479	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Jun, 2030 (7 years from now)
US9309229	NOVARTIS	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine	Jan, 2032 (9 years from now)
CN101514191A	NOVARTIS	Method Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds	Jun, 2011 (11 years ago)
CN102317268A	NOVARTIS	2-Biphenylamion-4-Aminopyrimidine Derivatives As Kinase Inhibitors	Jul, 2014 (8 years ago)
CN101616895A	NOVARTIS	Compounds And Compositions As Protein Kinase Inhibitors	Sep, 2014 (8 years ago)
CN103282359A	NOVARTIS	5-Chloro--N2-(2-Isopropoxy--5-Methyl--4-Piperidin--4-Yl-Phenyl)--N4-[2-(Propane--2-Sulfonyl)-Phenyl]--2, 4-Diamine In Crystalline Form.	Jun, 2017 (5 years ago)
CN104262324A	NOVARTIS	5 - -N2-(2-Isopropoxy - -5 - Methyl - -4 - Piperidine - -4 - Yl-Phenyl)--N4-[2 - (Propane - -2 - Sulphonyl) - Phenyl]--2, 4-Diamine In Crystalline Form	Jul, 2017 (5 years ago)
CN107056751A	NOVARTIS	Crystalline Form Of Alk Inhibitor	Mar, 2021 (1 year, 6 months ago)
CN1625400B	NOVARTIS	2, 4-Pyridine Diamine Compound And Application Thereof	Jan, 2023 (3 months from now)
CN1625400A	NOVARTIS	2, 4-Pyrimidine Diamine Compound And Use Thereof	Jan, 2023 (3 months from now)
CN102174024B	NOVARTIS	2, 4-Pyridine Diamine Compound And Application Thereof	Jan, 2023 (3 months from now)
CN102174024A	NOVARTIS	2,4-Pyrimidinediamine Compounds And Application Thereof	Jan, 2023 (3 months from now)
CN103169708A	NOVARTIS	Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds	Jul, 2023 (9 months from now)
CN103169708B	NOVARTIS	2, 4-Pyrimidine Diamine Compound For Treating Or Preventing Autoimmune Disease In A Subject	Jul, 2023 (9 months from now)
CN1788001B	NOVARTIS	2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
CN101921236B	NOVARTIS	2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
CN101921236A	NOVARTIS	2,4-Di(Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
CN1788001A	NOVARTIS	Can Be Used For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders For 2, 4-Di (Phenylamino) Pyrimidine	Mar, 2024 (1 year, 5 months from now)
CN1832929B	NOVARTIS	2, 4-Thonzylamine For Treating Neoplasia Disease, Inflammation And The Immune System Disorder	Mar, 2024 (1 year, 5 months from now)
CN1832929A	NOVARTIS	For Treating Neoplastic Disease, Inflammation, And Diseases Of The Immune System Of 2, 4-Pyrimidine Diamine	Mar, 2024 (1 year, 5 months from now)
IN200401139P2	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
IN239514B	NOVARTIS	2,4 - Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
IN200502241P4	NOVARTIS	2,4-Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
IN232653B	NOVARTIS	2,4-Di(Phenylamino)Pyrimidines For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
IN200600553P4	NOVARTIS	2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Aug, 2024 (1 year, 10 months from now)
IN240560B	NOVARTIS	2,4-Pyrimidinediamines And A Pharmaceutical Composition Comprising The Same	Aug, 2024 (1 year, 10 months from now)
IN200903951P1	NOVARTIS	Compounds And Compositions As Protein Kinase Inhibitors	Nov, 2027 (5 years from now)
IN276026B	NOVARTIS	Compounds And Compositions As Protein Kinase Inhibitors	Nov, 2027 (5 years from now)
EP2091918B1	NOVARTIS	Compounds And Compositions As Protein Kinase Inhibitors	Jul, 2020 (2 years ago)
EP2091918A2	NOVARTIS	Compounds And Compositions As Protein Kinase Inhibitors	Jul, 2020 (2 years ago)
EP2651918A1	NOVARTIS	Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine	Jun, 2022 (4 months ago)
EP2651918B1	NOVARTIS	Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine	Jun, 2022 (4 months ago)
EP2281563B1	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
EP1471915A2	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
EP2281563A1	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
EP1471915A4	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
EP1471915B1	NOVARTIS	2,4-Pyrimidinediamine Compounds And Their Uses	Jan, 2023 (3 months from now)
EP1534286B1	NOVARTIS	Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds	Jul, 2023 (9 months from now)
EP2316459B1	NOVARTIS	2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases	Jul, 2023 (9 months from now)
EP2316459A1	NOVARTIS	2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases	Jul, 2023 (9 months from now)
EP1534286A1	NOVARTIS	Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds	Jul, 2023 (9 months from now)
EP1606265A1	NOVARTIS	2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
EP1606265B1	NOVARTIS	2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
EP2275413B1	NOVARTIS	2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
EP2275413A1	NOVARTIS	2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Mar, 2024 (1 year, 5 months from now)
EP2287156A1	NOVARTIS	2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Aug, 2024 (1 year, 10 months from now)
EP1660458A1	NOVARTIS	2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Aug, 2024 (1 year, 10 months from now)
EP1660458B1	NOVARTIS	2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Aug, 2024 (1 year, 10 months from now)
EP2287156B1	NOVARTIS	2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders	Aug, 2024 (1 year, 10 months from now)
EP2311807B1	NOVARTIS	Compounds And Composition As Protein Kinase Inhibitors	Nov, 2027 (5 years from now)
EP2311807A1	NOVARTIS	Compounds And Composition As Protein Kinase Inhibitors	Nov, 2027 (5 years from now)
EP3121171B1	NOVARTIS	Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine	Dec, 2031 (9 years from now)
EP3453708B1	NOVARTIS	Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride	Dec, 2031 (9 years from now)
EP3121171A1	NOVARTIS	Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine	Dec, 2031 (9 years from now)
EP3453708A1	NOVARTIS	Process For The Preparation Of 5-Chloro-N-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N-2-(Isopropylsulfonyl)Phenyl)-2,4-Diamine Di-Hydrochloride	Dec, 2031 (9 years from now)
EP3453708B8	NOVARTIS	Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride	Dec, 2031 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921	NOVARTIS	Compounds and compositions as protein kinase inhibitors	Nov, 2027 (5 years from now)
US8703787	NOVARTIS	Methods of using ALK inhibitors	Feb, 2032 (9 years from now)

Drugs and Companies using CERITINIB ingredient

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

Pharsight

Drug Patents owned by Novartis

1. Drug name - AFINITOR

2. Drug name - AMTURNIDE

3. Drug name - ARCAPTA NEOHALER

4. Drug name - CIPRODEX

5. Drug name - EXFORGE HCT

6. Drug name - GILENYA

7. Drug name - HYCAMTIN

8. Drug name - ILEVRO

9. Drug name - IZBA

10. Drug name - KISQALI

11. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

12. Drug name - LEQVIO

13. Drug name - MAYZENT

14. Drug name - MEKINIST

15. Drug name - MOXEZA

16. Drug name - NEVANAC

17. Drug name - PATANASE

18. Drug name - PIQRAY

19. Drug name - PROMACTA

20. Drug name - PROMACTA KIT

21. Drug name - RECLAST

22. Drug name - RYDAPT

23. Drug name - SCEMBLIX

24. Drug name - SEEBRI

25. Drug name - TAFINLAR

26. Drug name - TASIGNA

27. Drug name - TEKAMLO

28. Drug name - TRAVATAN Z

29. Drug name - TRIESENCE

30. Drug name - TYKERB

31. Drug name - TYZEKA

32. Drug name - UTIBRON

33. Drug name - VALTURNA

34. Drug name - VOTRIENT

35. Drug name - XIIDRA

36. Drug name - ZOMETA

37. Drug name - ZYKADIA

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drug Patents owned by Novartis

1. Drug name - AFINITOR

2. Drug name - AMTURNIDE

3. Drug name - ARCAPTA NEOHALER

4. Drug name - CIPRODEX

5. Drug name - EXFORGE HCT

6. Drug name - GILENYA

7. Drug name - HYCAMTIN

8. Drug name - ILEVRO

9. Drug name - IZBA

10. Drug name - KISQALI

11. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

12. Drug name - LEQVIO

13. Drug name - MAYZENT

14. Drug name - MEKINIST

15. Drug name - MOXEZA

16. Drug name - NEVANAC

17. Drug name - PATANASE

18. Drug name - PIQRAY

19. Drug name - PROMACTA

20. Drug name - PROMACTA KIT

21. Drug name - RECLAST

22. Drug name - RYDAPT

23. Drug name - SCEMBLIX

24. Drug name - SEEBRI

25. Drug name - TAFINLAR

26. Drug name - TASIGNA

27. Drug name - TEKAMLO

28. Drug name - TRAVATAN Z

29. Drug name - TRIESENCE

30. Drug name - TYKERB

31. Drug name - TYZEKA

32. Drug name - UTIBRON

33. Drug name - VALTURNA

34. Drug name - VOTRIENT

35. Drug name - XIIDRA

36. Drug name - ZOMETA

37. Drug name - ZYKADIA

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.